首页 > 最新文献

International Journal of Toxicology最新文献

英文 中文
Electrophysiological Changes in the Rabbit Ventricular Wedge and Human-Induced Pluripotent Stem-Cell Derived (IPSC) Cardiomyocytes Translate to Severe Arrhythmia Observed in a Canine Toxicology Study, Not Predicted by Standard In Vitro Ion Channel Assays. 兔室楔和人类诱导多能干细胞衍生(IPSC)心肌细胞的电生理学变化转化为犬毒理学研究中观察到的严重心律失常,而标准体外离子通道测定无法预测这种变化。
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-05-01 Epub Date: 2024-02-08 DOI: 10.1177/10915818241230900
Alan P Brown, Gregory S Friedrichs, Hai-Ming Tang, Martin Traebert, Valerie Weber, Nancy Yao, Gan-Xin Yan

During drug discovery, small molecules are typically assayed in vitro for secondary pharmacology effects, which include ion channels relevant to cardiac electrophysiology. Compound A was an irreversible inhibitor of myeloperoxidase investigated for the treatment of peripheral artery disease. Oral doses in dogs at ≥5 mg/kg resulted in cardiac arrhythmias in a dose-dependent manner (at Cmax, free ≥1.53 μM) that progressed in severity with time. Nevertheless, a panel of 13 different cardiac ion channel (K, Na, and Ca) assays, including hERG, failed to identify pharmacologic risks of the molecule. Compound A and a related Compound B were evaluated for electrophysiological effects in the isolated rabbit ventricular wedge assay. Compounds A and B prolonged QT and Tp-e intervals at ≥1 and ≥.3 μM, respectively, and both prolonged QRS at ≥5 μM. Compound A produced early after depolarizations and premature ventricular complexes at ≥5 μM. These data indicate both compounds may be modulating hERG (Ikr) and Nav1.5 ion channels. In human IPSC cardiomyocytes, Compounds A and B prolonged field potential duration at ≥3 μM and induced cellular dysrhythmia at ≥10 and ≥3 μM, respectively. In a rat toxicology study, heart tissue: plasma concentration ratios for Compound A were ≥19X at 24 hours post-dose, indicating significant tissue distribution. In conclusion, in vitro ion channel assays may not always identify cardiovascular electrophysiological risks observed in vivo, which can be affected by tissue drug distribution. Risk for arrhythmia may increase with a "trappable" ion channel inhibitor, particularly if cardiac tissue drug levels achieve a critical threshold for pharmacologic effects.

在药物发现过程中,通常会在体外对小分子药物进行次级药理学效应化验,其中包括与心脏电生理学相关的离子通道。化合物 A 是一种不可逆的髓过氧化物酶抑制剂,用于治疗外周动脉疾病。狗口服剂量≥5 毫克/千克时会导致心律失常,其严重程度随时间推移呈剂量依赖性(Cmax 时,游离≥1.53 μM)。然而,包括 hERG 在内的 13 种不同的心脏离子通道(K、Na 和 Ca)检测方法均未能发现该分子的药理风险。在离体兔心室楔形试验中,对化合物 A 和相关化合物 B 的电生理效应进行了评估。化合物 A 和 B 分别在≥1 μM和≥.3 μM时延长了 QT 和 Tp-e 间期,在≥5 μM时均延长了 QRS。化合物 A 在≥5 μM时会产生早期除极和室性早搏。这些数据表明这两种化合物可能都在调节 hERG(Ikr)和 Nav1.5 离子通道。在人 IPSC 心肌细胞中,化合物 A 和 B 在≥3 μM 时可延长场电位持续时间,在≥10 和≥3 μM 时可分别诱导细胞节律失常。在一项大鼠毒理学研究中,剂量后 24 小时,化合物 A 的心脏组织:血浆浓度比≥19 倍,表明其在组织中的分布显著。总之,体外离子通道检测不一定总能确定体内观察到的心血管电生理风险,这可能会受到组织药物分布的影响。使用 "可捕获 "离子通道抑制剂可能会增加心律失常的风险,尤其是当心脏组织药物水平达到药理效应的临界阈值时。
{"title":"Electrophysiological Changes in the Rabbit Ventricular Wedge and Human-Induced Pluripotent Stem-Cell Derived (IPSC) Cardiomyocytes Translate to Severe Arrhythmia Observed in a Canine Toxicology Study, Not Predicted by Standard In Vitro Ion Channel Assays.","authors":"Alan P Brown, Gregory S Friedrichs, Hai-Ming Tang, Martin Traebert, Valerie Weber, Nancy Yao, Gan-Xin Yan","doi":"10.1177/10915818241230900","DOIUrl":"10.1177/10915818241230900","url":null,"abstract":"<p><p>During drug discovery, small molecules are typically assayed in vitro for secondary pharmacology effects, which include ion channels relevant to cardiac electrophysiology. Compound A was an irreversible inhibitor of myeloperoxidase investigated for the treatment of peripheral artery disease. Oral doses in dogs at ≥5 mg/kg resulted in cardiac arrhythmias in a dose-dependent manner (at Cmax, free ≥1.53 μM) that progressed in severity with time. Nevertheless, a panel of 13 different cardiac ion channel (K, Na, and Ca) assays, including hERG, failed to identify pharmacologic risks of the molecule. Compound A and a related Compound B were evaluated for electrophysiological effects in the isolated rabbit ventricular wedge assay. Compounds A and B prolonged QT and Tp-e intervals at ≥1 and ≥.3 μM, respectively, and both prolonged QRS at ≥5 μM. Compound A produced early after depolarizations and premature ventricular complexes at ≥5 μM. These data indicate both compounds may be modulating hERG (I<sub>kr</sub>) and Nav1.5 ion channels. In human IPSC cardiomyocytes, Compounds A and B prolonged field potential duration at ≥3 μM and induced cellular dysrhythmia at ≥10 and ≥3 μM, respectively. In a rat toxicology study, heart tissue: plasma concentration ratios for Compound A were ≥19X at 24 hours post-dose, indicating significant tissue distribution. In conclusion, in vitro ion channel assays may not always identify cardiovascular electrophysiological risks observed in vivo, which can be affected by tissue drug distribution. Risk for arrhythmia may increase with a \"trappable\" ion channel inhibitor, particularly if cardiac tissue drug levels achieve a critical threshold for pharmacologic effects.</p>","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":" ","pages":"231-242"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139702420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review. 死藤水和二甲基色胺的不良事件和毒性分析:系统性专题回顾。
IF 1.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-05-01 Epub Date: 2024-02-16 DOI: 10.1177/10915818241230916
Eleanor White, Tom Kennedy, Simon Ruffell, Daniel Perkins, Jerome Sarris

The objective of this paper is to conduct a systematic thematic review of adverse events, safety, and toxicity of traditional ayahuasca plant preparations and its main psychoactive alkaloids (dimethyltryptamine [DMT], harmine, harmaline, and tetrahydroharmine), including discussing clinical considerations (within clinical trials or approved settings). A systematic literature search of preclinical, clinical, epidemiological, and pharmacovigilance data (as well as pertinent reviews and case studies) was conducted for articles using the electronic databases of PubMed and Web of Science (to 6 July 2023) and PsycINFO, ClinicalTrials.gov, and Embase (to 21 September 2022) and included articles in English in peer-reviewed journals. Additionally, reference lists were searched. Due to the breadth of the area covered, we presented the relevant data in a thematic format. Our searches revealed 78 relevant articles. Data showed that ayahuasca or DMT is generally safe; however, some adverse human events have been reported. Animal models using higher doses of ayahuasca have shown abortifacient and teratogenic effects. Isolated harmala alkaloid studies have also revealed evidence of potential toxicity at higher doses, which may increase with co-administration with certain medications. Harmaline revealed the most issues in preclinical models. Nevertheless, animal models involving higher-dose synthetic isolates may not necessarily be able to be extrapolated to human use of therapeutic doses of plant-based extracts. Serious adverse effects are rarely reported within healthy populations, indicating an acceptable safety profile for the traditional use of ayahuasca and DMT in controlled settings. Further randomized, controlled trials with judicious blinding, larger samples, and longer duration are needed.

本文旨在对传统死藤植物制剂及其主要精神活性生物碱(二甲基色胺[DMT]、哈明、哈玛琳和四氢哈明)的不良事件、安全性和毒性进行系统的专题综述,包括讨论临床考虑因素(在临床试验或经批准的情况下)。我们使用 PubMed 和 Web of Science(截至 2023 年 7 月 6 日)以及 PsycINFO、ClinicalTrials.gov 和 Embase(截至 2022 年 9 月 21 日)电子数据库对临床前、临床、流行病学和药物警戒数据(以及相关综述和案例研究)进行了系统的文献检索,包括同行评审期刊中的英文文章。此外,还检索了参考文献目录。由于涉及领域广泛,我们以专题的形式展示了相关数据。通过检索,我们发现了 78 篇相关文章。数据显示,死藤水或 DMT 一般是安全的;但也有一些人类不良事件的报道。使用较高剂量死藤水的动物模型显示出堕胎和致畸作用。孤立的哈玛拉生物碱研究也显示,剂量较大时可能会产生毒性,与某些药物同时服用时毒性可能会增加。哈马林在临床前模型中暴露出的问题最多。不过,涉及较高剂量合成分离物的动物模型不一定能推断出人体使用治疗剂量的植物提取物的情况。在健康人群中,很少有严重不良反应的报道,这表明在受控环境下,死藤水和 DMT 的传统使用具有可接受的安全性。我们还需要进一步开展随机对照试验,试验应具有明智的盲法、更大的样本和更长的持续时间。
{"title":"Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review.","authors":"Eleanor White, Tom Kennedy, Simon Ruffell, Daniel Perkins, Jerome Sarris","doi":"10.1177/10915818241230916","DOIUrl":"10.1177/10915818241230916","url":null,"abstract":"<p><p>The objective of this paper is to conduct a systematic thematic review of adverse events, safety, and toxicity of traditional ayahuasca plant preparations and its main psychoactive alkaloids (dimethyltryptamine [DMT], harmine, harmaline, and tetrahydroharmine), including discussing clinical considerations (within clinical trials or approved settings). A systematic literature search of preclinical, clinical, epidemiological, and pharmacovigilance data (as well as pertinent reviews and case studies) was conducted for articles using the electronic databases of PubMed and Web of Science (to 6 July 2023) and PsycINFO, ClinicalTrials.gov, and Embase (to 21 September 2022) and included articles in English in peer-reviewed journals. Additionally, reference lists were searched. Due to the breadth of the area covered, we presented the relevant data in a thematic format. Our searches revealed 78 relevant articles. Data showed that ayahuasca or DMT is generally safe; however, some adverse human events have been reported. Animal models using higher doses of ayahuasca have shown abortifacient and teratogenic effects. Isolated harmala alkaloid studies have also revealed evidence of potential toxicity at higher doses, which may increase with co-administration with certain medications. Harmaline revealed the most issues in preclinical models. Nevertheless, animal models involving higher-dose synthetic isolates may not necessarily be able to be extrapolated to human use of therapeutic doses of plant-based extracts. Serious adverse effects are rarely reported within healthy populations, indicating an acceptable safety profile for the traditional use of ayahuasca and DMT in controlled settings. Further randomized, controlled trials with judicious blinding, larger samples, and longer duration are needed.</p>","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":" ","pages":"327-339"},"PeriodicalIF":1.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11088222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to "Eleventh Triennial Toxicology Salary Survey". 第十一次三年期毒理学薪酬调查 "更正。
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-05-01 Epub Date: 2023-12-23 DOI: 10.1177/10915818231218209
{"title":"Corrigendum to \"Eleventh Triennial Toxicology Salary Survey\".","authors":"","doi":"10.1177/10915818231218209","DOIUrl":"10.1177/10915818231218209","url":null,"abstract":"","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":" ","pages":"340-346"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11145510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138885013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toxicological Assessment of Higher Olefins in OECD TG 422 Repeated Dose and Reproductive /Developmental Toxicity Screening Tests in Han Wistar Rats. OECD TG 422重复给药和汉族Wistar大鼠生殖/发育毒性筛选试验中高级烯烃的毒理学评估。
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-05-01 Epub Date: 2023-11-07 DOI: 10.1177/10915818231210856
Quan Shi, Juan-Carlos Carrillo, Michael G Penman, Hua Shen, Colin M North, Sophie Jia, Tilly Borsboom-Patel, Yuan Tian, Fabienne Hubert, Jason C Manton, Peter J Boogaard

Higher olefins (HO) are used primarily as intermediates in the production of other chemicals, such as polymers, fatty acids, plasticizer alcohols, surfactants, lubricants, amine oxides, and detergent alcohols. The potential toxicity of five HO (i.e., 1-Octene, Nonene, Decene, Hexadecene, and 1-Octadecene) with carbon ranging from C8 to C18 was examined in a combined repeated dose and reproduction/developmental toxicity screening study (OECD TG 422). These five HO were administered to Han Wistar rats by gavage at 0 (controls), 100, 300, and 1000 mg/kg bw/day. As a group of substances, adaptive changes in the liver (liver weight increase without pathological evidence), as well as increased kidney weight in male rats, were observed in HO with carbon numbers from C8 to C10. The overall systemic no observed adverse effect level (NOAEL) for all HO was determined at 1000 mg/kg bw/day. In the reproductive/developmental toxicity assessment, offspring viability, size, and weights were reduced in litters from females treated with Nonene at 1000 mg/kg bw/day. The overall no observed effects level (NOEL) for reproductive toxicity was considered to be 300 mg/kg bw/day for Nonene and 1000 mg/kg bw/day for the other four HO, respectively. These data significantly enrich the database on the toxicity of linear and branched HO, allowing comparison with similar data published on a range of linear and branched HO. Comparisons between structural class and study outcome provide further supportive data in order to validate the read-across hypothesis as part of an overall holistic testing strategy.

高级烯烃(HO)主要用作生产其他化学品的中间体,如聚合物、脂肪酸、增塑剂醇、表面活性剂、润滑剂、胺氧化物和洗涤剂醇。在重复剂量和生殖/发育毒性联合筛选研究中,检测了五种HO(即1-辛烯、壬烯、癸烯、十六烯和1-十八烯)对C8至C18碳的潜在毒性(OECD TG 422)。这五种HO分别以0(对照)、100、300和1000 mg/kg bw/天灌胃给药于汉族Wistar大鼠。作为一组物质,在HO中观察到肝脏的适应性变化(在没有病理学证据的情况下肝脏重量增加),以及雄性大鼠肾脏重量增加,碳数从C8到C10。所有HO的全身无不良反应水平(NOAEL)测定为1000 mg/kg体重/天。在生殖/发育毒性评估中,用1000毫克/公斤体重/天的壬烯处理的雌性窝仔的后代生存能力、大小和重量都有所降低。生殖毒性的总体无观测效应水平(NOEL)被认为对壬烯分别为300毫克/公斤体重/天,对其他四种HO分别为1000毫克/公斤重量/天。这些数据显著丰富了关于线性和支链HO毒性的数据库,允许与一系列线性和支链HO的类似数据进行比较。结构类别和研究结果之间的比较提供了进一步的支持性数据,以验证作为整体测试策略一部分的跨读假设。
{"title":"Toxicological Assessment of Higher Olefins in OECD TG 422 Repeated Dose and Reproductive /Developmental Toxicity Screening Tests in Han Wistar Rats.","authors":"Quan Shi, Juan-Carlos Carrillo, Michael G Penman, Hua Shen, Colin M North, Sophie Jia, Tilly Borsboom-Patel, Yuan Tian, Fabienne Hubert, Jason C Manton, Peter J Boogaard","doi":"10.1177/10915818231210856","DOIUrl":"10.1177/10915818231210856","url":null,"abstract":"<p><p>Higher olefins (HO) are used primarily as intermediates in the production of other chemicals, such as polymers, fatty acids, plasticizer alcohols, surfactants, lubricants, amine oxides, and detergent alcohols. The potential toxicity of five HO (i.e., 1-Octene, Nonene, Decene, Hexadecene, and 1-Octadecene) with carbon ranging from C8 to C18 was examined in a combined repeated dose and reproduction/developmental toxicity screening study (OECD TG 422). These five HO were administered to Han Wistar rats by gavage at 0 (controls), 100, 300, and 1000 mg/kg bw/day. As a group of substances, adaptive changes in the liver (liver weight increase without pathological evidence), as well as increased kidney weight in male rats, were observed in HO with carbon numbers from C8 to C10. The overall systemic no observed adverse effect level (NOAEL) for all HO was determined at 1000 mg/kg bw/day. In the reproductive/developmental toxicity assessment, offspring viability, size, and weights were reduced in litters from females treated with Nonene at 1000 mg/kg bw/day. The overall no observed effects level (NOEL) for reproductive toxicity was considered to be 300 mg/kg bw/day for Nonene and 1000 mg/kg bw/day for the other four HO, respectively. These data significantly enrich the database on the toxicity of linear and branched HO, allowing comparison with similar data published on a range of linear and branched HO. Comparisons between structural class and study outcome provide further supportive data in order to validate the read-across hypothesis as part of an overall holistic testing strategy.</p>","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":" ","pages":"301-326"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71481530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vitro Safety Assessment of Extracts and Compounds From Plants as Sunscreen Ingredients. 植物提取物和化合物作为防晒成分的体外安全性评估。
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-05-01 Epub Date: 2024-01-06 DOI: 10.1177/10915818231225661
Silvia Juliana Flórez González, Elena E Stashenko, Raquel Elvira Ocazionez, María Pilar Vinardell, Jorge Luis Fuentes

This work investigated the safety of extracts obtained from plants growing in Colombia, which have previously shown UV-filter/antigenotoxic properties. The compounds in plant extracts obtained by the supercritical fluid (CO2) extraction method were identified using gas chromatography coupled to mass spectrometry (GC/MS) analysis. Cytotoxicity measured as cytotoxic concentration 50% (CC50) and genotoxicity of the plant extracts and some compounds were studied in human fibroblasts using the trypan blue exclusion assay and the Comet assay, respectively. The extracts from Pipper eriopodon and Salvia aratocensis species and the compound trans-β-caryophyllene were clearly cytotoxic to human fibroblasts. Conversely, Achyrocline satureioides, Chromolaena pellia, and Lippia origanoides extracts were relatively less cytotoxic with CC50 values of 173, 184, and 89 μg/mL, respectively. The C. pellia and L. origanoides extracts produced some degree of DNA breaks at cytotoxic concentrations. The cytotoxicity of the studied compounds was as follows, with lower CC50 values representing the most cytotoxic compounds: resveratrol (91 μM) > pinocembrin (144 μM) > quercetin (222 μM) > titanium dioxide (704 μM). Quercetin was unique among the compounds assayed in being genotoxic to human fibroblasts. Our work indicates that phytochemicals can be cytotoxic and genotoxic, demonstrating the need to establish safe concentrations of these extracts for their potential use in cosmetics.

这项研究调查了从哥伦比亚生长的植物中提取的萃取物的安全性,这些植物曾显示出紫外线过滤/抗原毒性特性。通过超临界流体(CO2)萃取法获得的植物提取物中的化合物采用气相色谱-质谱联用(GC/MS)分析法进行了鉴定。利用胰蓝排除法和彗星试验,分别研究了植物提取物和一些化合物在人成纤维细胞中的细胞毒性(以细胞毒性浓度 50%(CC50)计)和遗传毒性。Pipper eriopodon 和 Salvia aratocensis 的提取物以及化合物 trans-β-caryophyllene 对人类成纤维细胞具有明显的细胞毒性。相反,Achyrocline satureioides、Chromolaena pellia 和 Lippia origanoides 提取物的细胞毒性相对较低,CC50 值分别为 173、184 和 89 μg/mL。在细胞毒性浓度下,C. pellia 和 L. origanoides 提取物会产生一定程度的 DNA 断裂。研究化合物的细胞毒性如下,CC50 值越低,代表化合物的细胞毒性越强:白藜芦醇(91 μM)>松果菊素(144 μM)>槲皮素(222 μM)>二氧化钛(704 μM)。在所检测的化合物中,槲皮素对人类成纤维细胞的基因毒性是独一无二的。我们的研究结果表明,植物化学物质可能具有细胞毒性和基因毒性,因此有必要确定这些提取物的安全浓度,以便将其用于化妆品。
{"title":"In vitro Safety Assessment of Extracts and Compounds From Plants as Sunscreen Ingredients.","authors":"Silvia Juliana Flórez González, Elena E Stashenko, Raquel Elvira Ocazionez, María Pilar Vinardell, Jorge Luis Fuentes","doi":"10.1177/10915818231225661","DOIUrl":"10.1177/10915818231225661","url":null,"abstract":"<p><p>This work investigated the safety of extracts obtained from plants growing in Colombia, which have previously shown UV-filter/antigenotoxic properties. The compounds in plant extracts obtained by the supercritical fluid (CO<sub>2</sub>) extraction method were identified using gas chromatography coupled to mass spectrometry (GC/MS) analysis. Cytotoxicity measured as cytotoxic concentration 50% (CC<sub>50</sub>) and genotoxicity of the plant extracts and some compounds were studied in human fibroblasts using the trypan blue exclusion assay and the Comet assay, respectively. The extracts from <i>Pipper eriopodon</i> and <i>Salvia aratocensis</i> species and the compound <i>trans</i>-β-caryophyllene were clearly cytotoxic to human fibroblasts. Conversely, <i>Achyrocline satureioides</i>, <i>Chromolaena pellia</i>, and <i>Lippia origanoides</i> extracts were relatively less cytotoxic with CC<sub>50</sub> values of 173, 184, and 89 μg/mL, respectively. The <i>C. pellia</i> and <i>L. origanoides</i> extracts produced some degree of DNA breaks at cytotoxic concentrations. The cytotoxicity of the studied compounds was as follows, with lower CC<sub>50</sub> values representing the most cytotoxic compounds: resveratrol (91 μM) > pinocembrin (144 μM) > quercetin (222 μM) > titanium dioxide (704 μM). Quercetin was unique among the compounds assayed in being genotoxic to human fibroblasts. Our work indicates that phytochemicals can be cytotoxic and genotoxic, demonstrating the need to establish safe concentrations of these extracts for their potential use in cosmetics.</p>","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":" ","pages":"243-252"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139110948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety Assessment of Streptococcus salivarius UBSS-01 in Rats and Double-Blind Placebo-Controlled Study in Healthy Individuals 唾液链球菌 UBSS-01 在大鼠中的安全性评估和在健康人中的双盲安慰剂对照研究
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-27 DOI: 10.1177/10915818241247527
Bindhu S. Jatoth, Ziaur Rahman, Manoj P. Dandekar, Rajesh Venkataraman, Ravi K. Shivalingegowda, Gloriya G. Manuel
Streptococcus salivarius is a common, harmless, and prevalent member of the oral microbiota in humans. In the present study, the safety of S. salivarius UBSS-01 was evaluated using in silico methods and preclinical and clinical studies. In an acute toxicity study, rats were administered with 5 g/kg (500 × 109 CFU) S. salivarius UBSS-01. The changes in phenotypic behaviors and hematological, biochemical, electrolytes, and urine analyses were monitored. No toxicity was observed at 14 days post-treatment. The no observable effects limit (NOEL) of S. salivarius UBSS-01 was >5 g/kg in rats. In a 28-day repeat dose toxicity study, rats were administered S. salivarius UBSS-01 once daily at doses of 0.1, 0.5, and 1 g/kg (10, 50, and 100 billion CFU/kg, respectively) body weight. S. salivarius UBSS-01 did not influence any of the hematology parameters and clinical chemistry parameters in plasma and serum samples after 28-day repeated administration. No structural abnormality was observed in the histological examination of organs. Whole genome analysis revealed the absence of virulence factors or genes that may transmit antibiotic resistance. In the double-blind study with 60 human participants (aged 18–60 years), consumption of S. salivarius UBSS-01 for 30 days was found to be safe and results were comparable with placebo treatment These findings indicate that S. salivarius UBSS-01 may be safe for human consumption.
唾液链球菌是人类口腔微生物群中常见、无害且普遍的成员。本研究采用硅学方法和临床前及临床研究对唾液链球菌 UBSS-01 的安全性进行了评估。在急性毒性研究中,大鼠每公斤摄入 5 克(500 × 109 CFU)唾液酸酵母菌 UBSS-01。研究人员监测了大鼠的表型行为变化以及血液、生化、电解质和尿液分析。治疗后 14 天未观察到毒性。唾液腺单胞菌 UBSS-01 对大鼠的无观测效应限(NOEL)为 5 克/千克。在一项为期 28 天的重复剂量毒性研究中,按 0.1、0.5 和 1 克/千克(分别为 100、500 和 1000 亿 CFU/千克)的体重剂量给大鼠每天注射一次唾液球菌 UBSS-01。重复给药 28 天后,唾液球菌 UBSS-01 没有影响血浆和血清样本中的任何血液学参数和临床化学参数。器官组织学检查未发现结构异常。全基因组分析表明,不存在可能传播抗生素耐药性的毒力因子或基因。在对 60 名人类参与者(18-60 岁)进行的双盲研究中发现,连续 30 天食用唾液腺战士 UBSS-01 是安全的,其结果与安慰剂治疗相当。
{"title":"Safety Assessment of Streptococcus salivarius UBSS-01 in Rats and Double-Blind Placebo-Controlled Study in Healthy Individuals","authors":"Bindhu S. Jatoth, Ziaur Rahman, Manoj P. Dandekar, Rajesh Venkataraman, Ravi K. Shivalingegowda, Gloriya G. Manuel","doi":"10.1177/10915818241247527","DOIUrl":"https://doi.org/10.1177/10915818241247527","url":null,"abstract":"Streptococcus salivarius is a common, harmless, and prevalent member of the oral microbiota in humans. In the present study, the safety of S. salivarius UBSS-01 was evaluated using in silico methods and preclinical and clinical studies. In an acute toxicity study, rats were administered with 5 g/kg (500 × 10<jats:sup>9</jats:sup> CFU) S. salivarius UBSS-01. The changes in phenotypic behaviors and hematological, biochemical, electrolytes, and urine analyses were monitored. No toxicity was observed at 14 days post-treatment. The no observable effects limit (NOEL) of S. salivarius UBSS-01 was &gt;5 g/kg in rats. In a 28-day repeat dose toxicity study, rats were administered S. salivarius UBSS-01 once daily at doses of 0.1, 0.5, and 1 g/kg (10, 50, and 100 billion CFU/kg, respectively) body weight. S. salivarius UBSS-01 did not influence any of the hematology parameters and clinical chemistry parameters in plasma and serum samples after 28-day repeated administration. No structural abnormality was observed in the histological examination of organs. Whole genome analysis revealed the absence of virulence factors or genes that may transmit antibiotic resistance. In the double-blind study with 60 human participants (aged 18–60 years), consumption of S. salivarius UBSS-01 for 30 days was found to be safe and results were comparable with placebo treatment These findings indicate that S. salivarius UBSS-01 may be safe for human consumption.","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":"10 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140812420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dose Range-Finding Toxicity Study in Rats With Recombinant Human Lactoferrin Produced in Komagataella phaffii 用 Komagataella phaffii 生产的重组人乳铁蛋白对大鼠进行剂量范围毒性研究
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-22 DOI: 10.1177/10915818241247013
Ross Peterson, Robert B. Crawford, Lance K. Blevins, Norbert E. Kaminski, June S. Sass, Bryce Ferraro, Roma Vishwanath-Deutsch, Anthony J. Clark, Carrie-Anne Malinczak
The oral toxicity of recombinant human lactoferrin (rhLF, Helaina rhLF, Effera™) produced in Komagataella phaffii was investigated in adult Sprague Dawley rats by once daily oral gavage for 14 consecutive days. The study used groups of 3–6 rats/sex/dose. The vehicle control group received sodium citrate buffer, and the test groups received daily doses of 200, 1000, and 2000 mg of rhLF in sodium citrate buffer per kg body weight. Bovine LF at 2000 mg/kg body weight per day was used as a comparative control. Clinical observations, body weight, hematology, clinical chemistry, iron parameters, immunophenotyping, and gross examination at necropsy were used as criteria for detecting the effects of treatment in all groups and to help select dose levels for future toxicology studies. Quantitative LF levels were also analyzed as an indication of bioavailability. Overall, administration of Helaina rhLF by once daily oral gavage for 14 days was well tolerated in rats at levels up to 2000 mg/kg/day, or 57 × Helaina’s intended commercial use in adults, and indicating that a high dose of 2000 mg/kg/day is appropriate for future definitive toxicology studies.
研究人员以成年 Sprague Dawley 大鼠为研究对象,连续 14 天每天一次口服 Komagataella phaffii 中生产的重组人乳铁蛋白(rhLF、Helaina rhLF、Effera™)。研究采用 3-6 只大鼠/性别/剂量分组。载体对照组接受柠檬酸钠缓冲液,试验组接受柠檬酸钠缓冲液中的 rhLF,每日剂量分别为每公斤体重 200、1000 和 2000 毫克。每天每公斤体重 2000 毫克的牛血清磷脂作为对比对照。临床观察、体重、血液学、临床化学、铁参数、免疫分型和尸体解剖时的大体检查被用作检测所有组治疗效果的标准,并帮助选择未来毒理学研究的剂量水平。此外,还分析了LF的定量水平,作为生物利用率的指标。总体而言,大鼠对每日一次口服海拉那(Helaina)rhLF 14天的耐受性良好,最高剂量为2000毫克/千克/天,相当于海拉那(Helaina)在成人中的预期商业用量的57倍,这表明2000毫克/千克/天的高剂量适合用于未来的确定性毒理学研究。
{"title":"Dose Range-Finding Toxicity Study in Rats With Recombinant Human Lactoferrin Produced in Komagataella phaffii","authors":"Ross Peterson, Robert B. Crawford, Lance K. Blevins, Norbert E. Kaminski, June S. Sass, Bryce Ferraro, Roma Vishwanath-Deutsch, Anthony J. Clark, Carrie-Anne Malinczak","doi":"10.1177/10915818241247013","DOIUrl":"https://doi.org/10.1177/10915818241247013","url":null,"abstract":"The oral toxicity of recombinant human lactoferrin (rhLF, Helaina rhLF, Effera™) produced in Komagataella phaffii was investigated in adult Sprague Dawley rats by once daily oral gavage for 14 consecutive days. The study used groups of 3–6 rats/sex/dose. The vehicle control group received sodium citrate buffer, and the test groups received daily doses of 200, 1000, and 2000 mg of rhLF in sodium citrate buffer per kg body weight. Bovine LF at 2000 mg/kg body weight per day was used as a comparative control. Clinical observations, body weight, hematology, clinical chemistry, iron parameters, immunophenotyping, and gross examination at necropsy were used as criteria for detecting the effects of treatment in all groups and to help select dose levels for future toxicology studies. Quantitative LF levels were also analyzed as an indication of bioavailability. Overall, administration of Helaina rhLF by once daily oral gavage for 14 days was well tolerated in rats at levels up to 2000 mg/kg/day, or 57 × Helaina’s intended commercial use in adults, and indicating that a high dose of 2000 mg/kg/day is appropriate for future definitive toxicology studies.","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":"29 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140804396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recovery Animals in Toxicology Studies: An Innovation and Quality Consortium Perspective on Best Practices With Case Study Examples 恢复毒理学研究中的动物:创新与质量联合会的最佳实践视角及案例研究实例
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-12 DOI: 10.1177/10915818241243350
Smita Salian-Mehta, James D. Smith, Thierry D. Flandre, Amy L. Lambert, Joan H. Lane, Alan H. Stokes, Kathy Orsted, Natalie A. Bratcher-Petersen, Kyathanahalli S. Janardhan, Elizabeth G. Tonkin
The inclusion of recovery animals in nonclinical safety studies that support clinical trials is undertaken with a wide diversity of approaches even while operating under harmonized regulatory guidance. While empirical evaluation of reversibility may enhance the overall nonclinical risk assessment, there are often overlooked opportunities to reduce recovery animal use by leveraging robust scientific and regulatory information. In the past, there were several attempts to benchmark recovery practices; however, recommendations have not been consistently applied across the pharmaceutical industry. A working group (WG) sponsored by the 3Rs Translational and Predictive Sciences Leadership Group of the IQ Consortium conducted a survey of current industry practice related to the evaluation of reversibility/recovery in repeat dose toxicity studies. Discussion among the WG representatives included member company strategies and case studies that highlight challenges and opportunities for continuous refinements in the use of recovery animals. The case studies presented in this paper demonstrate increasing alignment with the Society of Toxicologic Pathology recommendations (2013) towards (1) excluding recovery phase cohorts by default (include only when scientifically justified), (2) minimizing the number of recovery groups (e.g., control and one dose level), and (3) excluding controls in the recovery cohort by leveraging external and/or dosing phase data. Recovery group exclusion and decisions regarding the timing of reversibility evaluation may be driven by indication, modality, and/or other scientific or strategic factors using a weight of evidence approach. The results and recommendations discussed present opportunities to further decrease animal use without impacting the quality of human risk assessment.
在支持临床试验的非临床安全性研究中使用恢复期动物的方法多种多样,即使是在统一的监管指导下也是如此。虽然对可逆性的经验评估可能会加强整体的非临床风险评估,但人们往往忽视了通过利用可靠的科学和监管信息来减少复原动物使用的机会。过去,人们曾多次尝试为恢复实践制定基准;但是,这些建议并没有在整个制药行业得到一致应用。由 IQ 联合会 3Rs 转化和预测科学领导小组赞助的一个工作组(WG)对当前行业中与重复剂量毒性研究中的可逆性/恢复性评估相关的实践进行了调查。工作组代表讨论的内容包括成员公司的策略和案例研究,这些策略和案例研究突出了在使用恢复期动物方面不断改进所面临的挑战和机遇。本文中介绍的案例研究表明,与毒理学病理学会的建议(2013 年)越来越一致,即:(1) 默认排除恢复期队列(仅在科学上合理时才纳入);(2) 尽量减少恢复组的数量(例如对照组和一个剂量水平);(3) 利用外部和/或剂量阶段数据排除恢复队列中的对照组。恢复组的排除和有关可逆性评估时机的决定可能受适应症、方式和/或其他科学或战略因素的驱动,采用证据权重法。所讨论的结果和建议为在不影响人类风险评估质量的情况下进一步减少动物使用提供了机会。
{"title":"Recovery Animals in Toxicology Studies: An Innovation and Quality Consortium Perspective on Best Practices With Case Study Examples","authors":"Smita Salian-Mehta, James D. Smith, Thierry D. Flandre, Amy L. Lambert, Joan H. Lane, Alan H. Stokes, Kathy Orsted, Natalie A. Bratcher-Petersen, Kyathanahalli S. Janardhan, Elizabeth G. Tonkin","doi":"10.1177/10915818241243350","DOIUrl":"https://doi.org/10.1177/10915818241243350","url":null,"abstract":"The inclusion of recovery animals in nonclinical safety studies that support clinical trials is undertaken with a wide diversity of approaches even while operating under harmonized regulatory guidance. While empirical evaluation of reversibility may enhance the overall nonclinical risk assessment, there are often overlooked opportunities to reduce recovery animal use by leveraging robust scientific and regulatory information. In the past, there were several attempts to benchmark recovery practices; however, recommendations have not been consistently applied across the pharmaceutical industry. A working group (WG) sponsored by the 3Rs Translational and Predictive Sciences Leadership Group of the IQ Consortium conducted a survey of current industry practice related to the evaluation of reversibility/recovery in repeat dose toxicity studies. Discussion among the WG representatives included member company strategies and case studies that highlight challenges and opportunities for continuous refinements in the use of recovery animals. The case studies presented in this paper demonstrate increasing alignment with the Society of Toxicologic Pathology recommendations (2013) towards (1) excluding recovery phase cohorts by default (include only when scientifically justified), (2) minimizing the number of recovery groups (e.g., control and one dose level), and (3) excluding controls in the recovery cohort by leveraging external and/or dosing phase data. Recovery group exclusion and decisions regarding the timing of reversibility evaluation may be driven by indication, modality, and/or other scientific or strategic factors using a weight of evidence approach. The results and recommendations discussed present opportunities to further decrease animal use without impacting the quality of human risk assessment.","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":"1 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140577692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editor’s Note 编者按
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-04 DOI: 10.1177/10915818241245479
Mary Beth Genter
{"title":"Editor’s Note","authors":"Mary Beth Genter","doi":"10.1177/10915818241245479","DOIUrl":"https://doi.org/10.1177/10915818241245479","url":null,"abstract":"","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":"86 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140577623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety Assessment of Zinc Salts as Used in Cosmetics. 化妆品中使用的锌盐的安全性评估。
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-01 Epub Date: 2024-01-27 DOI: 10.1177/10915818241227124
Laura N Scott, Monice Fiume, Jinqiu Zhu, Wilma F Bergfeld, Donald V Belsito, Ronald A Hill, Curtis D Klaassen, Daniel C Liebler, James G Marks, Ronald C Shank, Thomas J Slaga, Paul W Snyder, Bart Heldreth

The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of 27 inorganic and organometallic zinc salts as used in cosmetic formulations; these salts are specifically of the 2+ (II) oxidation state cation of zinc. These ingredients included in this report have various reported functions in cosmetics, including hair conditioning agents, skin conditioning agents, cosmetic astringents, cosmetic biocides, preservatives, oral care agents, buffering agents, bulking agents, chelating agents, and viscosity increasing agents. The Panel reviewed the relevant data for these ingredients, and concluded that these 27 ingredients are safe in cosmetics in the present practices of use and concentration described in this safety assessment when formulated to be non-irritating.

化妆品成分安全专家小组(专家小组)对化妆品配方中使用的 27 种无机和有机金属锌盐的安全性进行了评估;这些锌盐特别是锌的 2+ (II) 氧化态阳离子。据报告,本报告中的这些成分在化妆品中具有各种功能,包括头发调理剂、皮肤调理剂、化妆品收敛剂、化妆品杀菌剂、防腐剂、口腔护理剂、缓冲剂、膨松剂、螯合剂和增粘剂。专家小组审查了这些成分的相关数据,得出结论认为,按照本安全评估中所述的现行使用方法和浓度,这 27 种成分在配制成无刺激性的化妆品中是安全的。
{"title":"Safety Assessment of Zinc Salts as Used in Cosmetics.","authors":"Laura N Scott, Monice Fiume, Jinqiu Zhu, Wilma F Bergfeld, Donald V Belsito, Ronald A Hill, Curtis D Klaassen, Daniel C Liebler, James G Marks, Ronald C Shank, Thomas J Slaga, Paul W Snyder, Bart Heldreth","doi":"10.1177/10915818241227124","DOIUrl":"10.1177/10915818241227124","url":null,"abstract":"<p><p>The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of 27 inorganic and organometallic zinc salts as used in cosmetic formulations; these salts are specifically of the <sup>2+</sup> (II) oxidation state cation of zinc. These ingredients included in this report have various reported functions in cosmetics, including hair conditioning agents, skin conditioning agents, cosmetic astringents, cosmetic biocides, preservatives, oral care agents, buffering agents, bulking agents, chelating agents, and viscosity increasing agents. The Panel reviewed the relevant data for these ingredients, and concluded that these 27 ingredients are safe in cosmetics in the present practices of use and concentration described in this safety assessment when formulated to be non-irritating.</p>","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":" ","pages":"5S-69S"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139570305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Toxicology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1